De novo design of D-peptide ligands: Application to influenza virus hemagglutinin
Abstract
D-peptides hold great promise as therapeutics by alleviating the challenges of metabolic stability and immunogenicity in L-peptides. However, current D-peptide discovery methods are severely limited by specific size, structure, and the chemical synthesizability of their protein targets. Here, we describe a computational method for de novo design of D-peptides that bind to an epitope of interest on the target protein using Rosetta’s hotspot-centric approach. The approach comprises identifying hotspot sidechains in a functional protein–protein interaction and grafting these side chains onto much smaller structured peptide scaffolds of opposite chirality. The approach enables more facile design of D-peptides and its applicability is demonstrated by design of D-peptidic binders of influenza A virus hemagglutinin, resulting in identification of multiple D-peptide lead series. The X-ray structure of one of the leads at 2.38 Å resolution verifies the validity of the approach. This method should be generally applicable to targets with detailed structural information, independent of molecular size, and accelerate development of stable, peptide-based therapeutics.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (14)
Jarek Juraszek
Johnson and Johnson Innovative Medicine
Rameshwar U. Kadam
Department of Integrative Structural and Computational Biology, The Scripps Research Institute
Davide Branduardi
Johnson and Johnson Innovative Medicine
Jeroen van Ameijde
Divita Garg
Department of Molecular Medicine, The Scripps Research Institute
Nicolas Dailly
Johnson and Johnson Innovative Medicine
Mandy Jongeneelen
Johnson and Johnson Innovative Medicine
Jan Vermond
Johnson and Johnson Innovative Medicine
Just P. J. Brakenhoff
Johnson and Johnson Innovative Medicine
Boerries Brandenburg
Johnson and Johnson Innovative Medicine
Maria J. P. van Dongen
Johnson and Johnson Innovative Medicine
Ronald Vogels
Johnson and Johnson Innovative Medicine
Robert H. E. Friesen
Johnson and Johnson Innovative Medicine
Ian A. Wilson